We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

39 hedge funds and large institutions have $37.4M invested in Cue Biopharma in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

44% more capital invested

Capital invested by funds: $25.9M → $37.4M (+$11.4M)

34% more funds holding

Funds holding: 29 → 39 (+10)

0.21% more ownership

Funds ownership: 0.32% → 0.52% (+0.21%)

Holders
39
Holders Change
+10
Holders Change %
+34.48%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.46M
2
NCM
Nantahala Capital Management
Connecticut
+$5.61M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.87M
4
Northern Trust
Northern Trust
Illinois
+$1.4M
5
State Street
State Street
Massachusetts
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
First Eagle Investment Management
First Eagle Investment Management
New York
-$4.04M
2
Citigroup
Citigroup
New York
-$458K
3
VF
Virtu Financial
New York
-$232K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$15.1K
5
Barclays
Barclays
United Kingdom
-$7.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
DOA
26
D'Orazio & Associates
Virginia
$95K +$106K +267 New
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$52K +$57.2K +144 New
JP Morgan Chase
28
JP Morgan Chase
New York
$43K +$23.9K +60 +100%
Bank of America
29
Bank of America
North Carolina
$37K +$31.8K +80 +364%
Legal & General Group
30
Legal & General Group
United Kingdom
$31K +$14.3K +36 +69%
SO
31
STRS Ohio
Ohio
$29K – – –
AIP
32
Ameritas Investment Partners
Nebraska
$19K +$11.1K +28 +112%
Barclays
33
Barclays
United Kingdom
$15K -$7.16K -18 -30%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$7.17K -$15.1K -38 -66%
TRCT
35
Tower Research Capital (TRC)
New York
$4K -$1.19K -3 -21%
PIA
36
Piedmont Investment Advisors
North Carolina
$4K +$3.98K +10 New
LTFS
37
Ladenburg Thalmann Financial Services
Florida
$2K – – –
PNC Financial Services Group
38
PNC Financial Services Group
Pennsylvania
$2K – – –
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$1K +$1.59K +4 New
VF
40
Virtu Financial
New York
– -$232K -551 Closed
1
2

CUE Hedge Fund Activity: Q2 2018 in Review

39 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2018, worth a combined $37.4M — up 44% from $25.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 1 closed out — a net gain of 10 holders — while 19 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $6.46M. The largest seller was First Eagle Investment Management, cutting an estimated $4.04M.

  • 39 institutional investors held Cue Biopharma (CUE) as of Q2 2018, up from 29 in Q1 2018.
  • Funds reported $37.4M of Cue Biopharma stock for Q2 2018, up 44% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q2 2018 and 1 closed out, a net change of +10 holders.
  • The largest Cue Biopharma buyer in Q2 2018 was BlackRock, an estimated $6.46M added.
  • The largest Cue Biopharma seller in Q2 2018 was First Eagle Investment Management, an estimated $4.04M sold.

Based on aggregated 13F filings for Q2 2018.